John G Ullman & Associates Inc. Sells 300 Shares of Baxter International Inc (NYSE:BAX)

John G Ullman & Associates Inc. lessened its stake in Baxter International Inc (NYSE:BAX) by 0.5% in the second quarter, HoldingsChannel reports. The firm owned 55,426 shares of the medical instruments supplier’s stock after selling 300 shares during the period. John G Ullman & Associates Inc.’s holdings in Baxter International were worth $4,539,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BAX. Chemical Bank grew its stake in Baxter International by 2.4% in the second quarter. Chemical Bank now owns 14,808 shares of the medical instruments supplier’s stock valued at $1,213,000 after acquiring an additional 343 shares during the period. Dimensional Fund Advisors LP grew its stake in Baxter International by 1.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,205,779 shares of the medical instruments supplier’s stock valued at $79,362,000 after acquiring an additional 17,633 shares during the period. Archford Capital Strategies LLC grew its stake in Baxter International by 60.0% in the first quarter. Archford Capital Strategies LLC now owns 800 shares of the medical instruments supplier’s stock valued at $65,000 after acquiring an additional 300 shares during the period. Evolution Wealth Advisors LLC acquired a new position in Baxter International in the second quarter valued at about $32,000. Finally, Diversified Trust Co grew its stake in Baxter International by 17.8% in the first quarter. Diversified Trust Co now owns 42,508 shares of the medical instruments supplier’s stock valued at $3,456,000 after acquiring an additional 6,420 shares during the period. Institutional investors and hedge funds own 83.96% of the company’s stock.

In other news, SVP Jacqueline Kunzler sold 593 shares of the company’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $80.46, for a total transaction of $47,712.78. Following the completion of the transaction, the senior vice president now directly owns 9,023 shares of the company’s stock, valued at $725,990.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John D. Forsyth sold 1,320 shares of the company’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $78.21, for a total value of $103,237.20. Following the transaction, the director now directly owns 32,779 shares of the company’s stock, valued at $2,563,645.59. The disclosure for this sale can be found here. 0.70% of the stock is owned by corporate insiders.

A number of research firms have issued reports on BAX. Royal Bank of Canada set a $87.00 target price on Baxter International and gave the company a “hold” rating in a research note on Friday, July 26th. Raymond James boosted their target price on Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Piper Jaffray Companies boosted their target price on Baxter International from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. BMO Capital Markets boosted their target price on Baxter International to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Finally, Credit Suisse Group boosted their target price on Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 26th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Baxter International presently has an average rating of “Buy” and an average target price of $85.27.

Shares of BAX stock traded up $1.19 on Friday, hitting $86.97. 1,573,500 shares of the stock were exchanged, compared to its average volume of 2,442,591. The company has a current ratio of 2.78, a quick ratio of 2.10 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $43.83 billion, a P/E ratio of 28.51, a price-to-earnings-growth ratio of 1.99 and a beta of 1.00. The business has a 50-day moving average of $83.63 and a 200 day moving average of $78.28. Baxter International Inc has a fifty-two week low of $61.05 and a fifty-two week high of $88.28.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.08. The company had revenue of $2.84 billion during the quarter, compared to analysts’ expectations of $2.80 billion. Baxter International had a return on equity of 21.21% and a net margin of 14.28%. Baxter International’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.77 earnings per share. As a group, research analysts forecast that Baxter International Inc will post 3.37 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 1st. Stockholders of record on Friday, August 30th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Thursday, August 29th. This represents a $0.88 annualized dividend and a dividend yield of 1.01%. Baxter International’s dividend payout ratio is currently 28.85%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Read More: How are Outstanding Shares Different from Authorized Shares?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.